Bernie Shakes Up Biotech; Anixa Insider Takes Advantage

As the pre-election momentum builds around "MediCare For All", healthcare stocks have become quite jittery. Drug stocks, and in particular the biotech companies, have...

US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology

Tailwinds' Take: this is a very positive step for Anixa as it insures that they have rights to this treatment as a platform for...

Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology

Tailwinds' Take: I believe investors don't quite get the lack of support for the PSA in the medical community. Cchek, if and when approved,...

Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting

SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to...

Anixa’s CEO to Present at Major Cancer Symposium

On May 15th, Dr. Amit Kumar will be on a panel discussing cancer therapies for solid tumors. This panel is at a conference hosted...

U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate...

Tailwinds' Take: two keys to this press release. First, this should provide a steady stream of samples, keeping the timeline intact for developing the...

Anixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference

Tailwinds' Take: another oral presentation, at a key conference no less, is going to help Cchek gain recognition right before its launch. Interestingly, data...

Anixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for...

Tailwinds' Take: this is positive for a couple reasons. Oral presentations are not handed out willy-nilly...it shows that the medical community is catching on...

Anixa Partners With ResearchDX…Tailwinds’ Take

This morning, Anixa announced that they have achieved one of their key milestones for 2019, namely that of partnering with an independent clinical laboratory...

Anixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek™ Prostate Cancer Confirmation Test

Tailwinds' Take: Anixa is executing to their plan. Having a diagnostic in the market by Q3 should be eye-opening for institutional investors who have...

Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor...

Tailwinds' Take: working with the leader in MDSC research has enabled the progress of their Cchek diagnostic and will likely lead to more potential...

Oncocyte Jumps, Anixa Should Benefit

Shares in Oncocyte (OCX) are up over 200% today. This move is on the back of positive results from their liquid biopsy diagnostic for...

Anixa Doesn’t Disappoint…

On Thursday January 24th, Anixa Biosciences held an investor update call. In the preview to the call, management had talked about 2019 being a...

Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance

Tailwinds' Take: excellent news for ANIX. Their CAR-T therapy, being developed in partnership with Moffitt Cancer Center, has not only shown efficacy in ovarian...

Anixa Biosciences to Hold Conference Call to Discuss Outlook for 2019

Tailwinds' Take: we are very excited for this call. "Transformative" is the key word from this press release as it hints at major successes...

Anixa Call On January 24th Could Be Catalyst

When last we spoke with Anixa, they had just finished meeting with the FDA to discuss their Cchek program. The Company has scheduled a...

Tailwinds Top 8 Surprises for 2019

Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the...

The Answer To The Question

Well, I must have been very bad this year as it appears Santa Claus isn't coming to town. The market is trying...

Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic...

Tailwinds' Take: this is a positive development as ANIX moves towards potentially having a diagnostic product during 2019. Our opinion is that...

Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast...

Tailwinds' Take: more positive data just before they meet with the FDA. Important notes from the data include potential "Phase 0" detection and the...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.